EMA accepts GSK’s bepirovirsen filing in chronic hepatitis B: full analysis

GSK has cleared an early but important regulatory hurdle in Europe for bepirovirsen, announcing on March 27, 2026 that the EMA accepted its marketing authorisation application for review in adults with chronic hepatitis B. The candidate is an antisense oligonucleotide designed to target hepatitis B viral RNA, and GSK is positioning it as a possible first-in-class option after phase III B-Well 1 and B-Well 2 trials met their primary endpoints and showed higher functional cure rates than standard of care alone. (sec.gov)

The filing builds on several years of development in a field that has long struggled to move beyond viral suppression. Current standard treatment with nucleos(t)ide analogues can control chronic hepatitis B, but it often requires lifelong therapy and rarely delivers functional cure. GSK has repeatedly framed bepirovirsen around that unmet need, and the company’s earlier phase IIb B-Clear program, published in The New England Journal of Medicine in 2022, helped establish proof of concept for the asset, especially in patients with lower baseline hepatitis B surface antigen levels. (sec.gov)

In its SEC filing, GSK said the EMA submission is backed by positive results from the global, randomized, double-blind, placebo-controlled B-Well 1 and B-Well 2 studies, conducted across 29 countries. The trials enrolled nucleos(t)ide analogue-treated participants with chronic hepatitis B and baseline HBsAg of 3,000 IU/mL or less. According to GSK, both studies met the primary endpoint, with statistically significant results across ranked endpoints, including a stronger effect in the subgroup with baseline HBsAg of 1,000 IU/mL or less. The company also said the safety and tolerability profile was consistent with prior studies. (sec.gov)

Mechanistically, bepirovirsen is meant to do more than suppress replication. GSK describes it as a “triple action” antisense oligonucleotide that promotes destruction of hepatitis B viral mRNA and pregenomic RNA, lowers circulating HBsAg, inhibits viral replication, and may help restore immune control. That mechanistic story has been part of the program since earlier clinical work, including a phase II randomized controlled trial reported in Nature Medicine, which showed antiviral activity and helped support dose development. (sec.gov)

Public expert commentary on the EMA acceptance itself appears limited so far, but the broader scientific reaction to the program has been more visible. In GSK’s 2022 B-Clear announcement, principal investigator Professor Man-Fung Yuen said the data suggested a possible path to functional cure, particularly in patients with low baseline HBsAg levels. That view aligns with GSK’s later phase III messaging, which continued to highlight stronger outcomes in lower-HBsAg subgroups. Separately, the EMA has acknowledged in its revised hepatitis B guideline work that new products and treatment strategies are increasingly focused on functional cure, finite regimens, and novel antiviral or immunomodulatory mechanisms. (gsk.com)

Why it matters: For veterinary professionals, this isn’t a companion-animal therapeutic story, but it is a useful marker of where antiviral drug development is heading. Bepirovirsen sits at the intersection of nucleic acid therapeutics, finite-course treatment design, and immune-control strategies, all of which are relevant concepts well beyond human hepatology. It also shows how regulators are adapting to therapies that aim for functional cure rather than chronic suppression, a shift that could influence expectations for translational virology and future comparative medicine research. (sec.gov)

There’s also a commercial and regulatory signal here. GSK licensed bepirovirsen from Ionis and is now advancing parallel reviews in Europe and the U.S. After the EMA accepted the MAA in March, the FDA accepted the NDA for priority review and granted Breakthrough Therapy Designation on April 28, 2026, setting a PDUFA date of October 26, 2026. That sequence suggests GSK sees the phase III package as strong enough to support coordinated major-market filings, even before full congress presentation and peer-reviewed publication of the pivotal data. (sec.gov)

What to watch: The next milestones are detailed B-Well data disclosure at a 2026 medical congress, peer-reviewed publication, and signs of how regulators weigh subgroup effects, durability of response, and safety in the context of a finite-treatment “functional cure” claim. The FDA’s October 26, 2026 action date offers the clearest near-term regulatory marker, while the EMA review will show how Europe handles a first-wave hepatitis B application built around that newer endpoint framework. (sec.gov)